Pomerantz investigates Biogen over CELIA study disclosures
Pomerantz LLP is investigating Biogen Inc. for potential securities fraud and unlawful business practices related to the Phase 2 CELIA study. The investigation follows a 6.43% stock drop on May 14, 2026, after the study missed its primary endpoint despite Biogen calling results "compelling." Investors are advised to contact Danielle Peyton regarding potential losses.
*this image is generated using AI for illustrative purposes only.
Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. regarding potential violations of federal securities laws. The investigation focuses on whether Biogen and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. This scrutiny follows the company's announcement regarding the Phase 2 CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide therapy targeting tau in individuals with early Alzheimer's disease.
On May 14, 2026, Biogen issued a press release announcing topline results from the study. Although the company described the results as "compelling," the study missed its primary dose-response endpoint. Following this news, Biogen's stock price fell $13.16 per share, or 6.43%, to close at $191.37 per share on the same day.
The legal review aims to determine if investors suffered losses due to potential securities law violations related to these disclosures. Pomerantz LLP, acknowledged as a premier firm in corporate, securities, and antitrust class litigation, is conducting the investigation. The firm has offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv.
Investors who incurred losses are encouraged to participate. Danielle Peyton at Pomerantz LLP is available to discuss investor rights. Shareholders can contact the firm at newaction@pomlaw.com or by phone at 646-581-9980, ext. 7980.
| Key Details | Information |
|---|---|
| Company | Biogen Inc. |
| Ticker | NASDAQ: BIIB |
| Investigation Focus | Potential securities fraud |
| Event Date | May 14, 2026 |
| Stock Impact | -$13.16 (-6.43%) |
Pomerantz LLP was founded by the late Abraham L. Pomerantz, known as the dean of the class action bar. The firm has recovered numerous multimillion-dollar damages awards on behalf of class members. Additional information is available at www.pomlaw.com .
How will the failure of the CELIA study's primary endpoint impact Biogen's future R&D strategy for tau-targeting therapies?
What are the potential financial liabilities for Biogen if the securities fraud investigation leads to a class action settlement?
Will Biogen pivot its Alzheimer's pipeline resources toward other mechanisms of action following the diranersen results?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
